行情

VTGN

VTGN

VistaGen
NASDAQ

实时行情|Nasdaq Last Sale

0.4000
-0.0209
-4.97%
交易中 09:41 04/02 EDT
开盘
0.4176
昨收
0.4209
最高
0.4200
最低
0.4000
成交量
1.07万
成交额
--
52周最高
1.486
52周最低
0.2943
市值
1,918.52万
市盈率(TTM)
-0.6636
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测VTGN价格均价为1.000,最高价位1.000,最低价为1.000。

EPS

VTGN 新闻

更多
  • 瑞幸咖啡报告财报审计问题:伪造交易价值约22亿元
  • 新浪科技 · 46分钟前
  • 湖北农产品,淘宝销量翻倍
  • 新浪财经 · 48分钟前
  • 瑞幸咖啡盘前跌72% 调查称伪造交易价值大约22亿元
  • 新浪财经 · 55分钟前
  • 波音向员工提出自愿离职买断计划
  • 新浪财经 · 1小时前

所属板块

制药
-0.34%
制药与医学研究
-0.25%

热门股票

代码
价格
涨跌幅

VTGN 简况

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS). Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard antidepressants approved by the United States Food and Drug Administration (FDA). In addition to AV-101, the Company has developed a human pluripotent stem cell (hPSC) technology platform, which includes its in-vitro bioassay system, CardioSafe 3D, to predict potential heart toxicity of new chemical entities (NCEs) long before testing in animal and human studies. The Company is focused on regenerative medicine (RM) applications using blood, cartilage, heart and/or liver cells derived from hPSCs.
展开

微牛提供Vistagen Therapeutics Inc(NASDAQ-VTGN)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的VTGN股票新闻,以帮助您做出投资决策。